Evogene WKN: A0Q7UP ISIN: IL0011050551 Kürzel: E3V

Kurs zur EVOGENE Aktie
0,89 USD
-2,20 %-0,02
28. May, 02:00:00 Uhr, Nasdaq
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Summer.76
Summer.76, 10. Mär 13:56
https://www.prnewswire.com/il/news-releases/evogene-reports-fourth-quarter-and-full-year-2021-financial-results-301499893.html
Summer.76
Summer.76, 31.01.2022 18:07
https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Announces-Shipment-of-its-Cannabis-Varieties-to-Europe-37697124/
Summer.76
Summer.76, 17.11.2021 14:45
Evogene Reports Third Quarter 2021 Financial Results https://www.prnewswire.com/news-releases/evogene-reports-third-quarter-2021-financial-results-301426621.html
Summer.76
Summer.76, 10.11.2021 16:00
Evogene Announces Participation in the Second Research Period of the CRISPR-IL Consortium https://www.prnewswire.com/news-releases/evogene-announces-participation-in-the-second-research-period-of-the-crispr-il-consortium-301420838.html Israeli Innovation Authority to continue funding the on-going development of an end-to-end artificial intelligence system for genome-editing
Summer.76
Summer.76, 03.11.2021 14:23
Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - result™ https://www.prnewswire.com/news-releases/lavie-bio-announces-commercial-launch-of-its-first-microbiome-based-product-for-yield-improvement---result-301415083.html
Summer.76
Summer.76, 27.10.2021 15:23
Evogene subsidiary Biomica signs pact for cancer trial on microbiome-based asset https://seekingalpha.com/news/3758941-evogene-subsidiary-biomica-signs-pact-for-cancer-trial-on-microbiome-based-asset Biomica, a subsidiary of Evogene (NASDAQ:EVGN), has formed a clinical trial agreement (CTA) with the Israeli healthcare institution, Rambam Health Care Campus, to start the first-in-human  proof-of-concept study for BMC128. In the Phase 1 study, the microbiome-based immuno-oncology drug candidate developed by Biomica will be evaluated for safety and tolerability in combination with anti-PD-1 in patients with Non-small Cell Lung Cancer (NSCLC), Melanoma, or Renal Cell Carcinoma (RCC). The beginning of the trial is subject to clearance from the Israeli Ministry of Health ((MoH)). “Based on the compelling preclinical results achieved to-date, we are thrilled to take this next step in advancing BMC128 through the clinical development process,” CEO of Biomica Elran Haber noted. In April, the company disclosed pre-clinical results for BMC128 in melanoma, causing Evogene (EVGN) shares to gain in the pre-market.
Summer.76
Summer.76, 19.10.2021 15:48
Evogene : Canonic moves ahead of schedule with the full commercial launch of its G-nnovation products, following positive feedback from patients during the company's pre-launch campaign - Form 6-K https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Canonic-moves-ahead-of-schedule-with-the-full-commercial-launch-of-its-G-nnovation-product-36715825/
Summer.76
Summer.76, 29.09.2021 15:40
https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Lavie-Bio-and-United-Agronomy-Announce-Signing-of-Distribution-Agreement-for-Lavie-Bio-s-I-36548784/
Summer.76
Summer.76, 31.08.2021 17:39
Evogene : Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Canonic-Announces-Pre-Launch-of-its-First-Generation-Medical-Cannabis-Products-in-Israel-36288842/ Pre-launch of G-nnovation product line to a limited number of patients; Full commercial launch expected in 2022
Summer.76
Summer.76, 11.08.2021 13:23
Evogene Reports Second Quarter 2021 Financial Results https://finance.yahoo.com/news/evogene-reports-second-quarter-2021-110000165.html https://www.earningswhispers.com/epsdetails/evgn Evogene Ltd Ord (EVGN) reported a 2nd Quarter June 2021 loss of $0.15 per share on revenue of $0.1 million. on revenue of $0.3 million. Revenue fell 54.7% compared to the same quarter a year ago.
Kommentare
1 EVOGENE Hauptdiskussion
Kursdetails
Geld (bid) 0,89 (1.500)
Brief (ask/offer) 0,90 (500)
Spread 1,11
Geh. Stück 310 Tsd.
Eröffnung 0,90
Vortag 0,91
Tageshoch 0,93
Tagestief 0,89
52W Hoch 4,10
52W Tief 0,81
Tagesvolumen
in USD gehandelt 310 Tsd. Stk
Gesamt 310 Tsd. Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Nasdaq 0,89 0,90 1653696000 28. May 310.184 Stk 0,89 USD
AMEX 1653696000 28. May 100 Stk 0,89 USD
London 1652277124 11. May 0,92 USD
ges. 310.284 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
2,7 Mrd.
Anzahl der Aktien
35,6 Mio.
Grundlegende Daten zur EVOGENE Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.